Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; Data from a large and unselected Norwegian cohort

Annals of the Rheumatic Diseases

Volumn 74, Issue 8, 2015, Pages 1551-1556

  Dobloug, Cecilie ^a   Garen, Torhild ^a   Bitter, Helle ^b   Stjärne, Johan ^c   Stenseth, Guri ^d   Grøvle, Lars ^e   Sem, Marthe ^e   Gran, Jan Tore ^a   Molberg, Øyvind ^a,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Sørlandets Sykehus ^*  (Norway)

^c Betanien Hospital   (Norway)

^d Hospital for Rheumatic Diseases   (Norway)

^e Sykehuset Ostfold   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

JO 1 ANTIBODY; MI 2 ANTIBODY; PL 12 ANTIBODY; PL 7 ANTIBODY; PROTEIN ANTIBODY; SIGNAL RECOGNITION PARTICLE; SIGNAL RECOGNITION PARTICLE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRITIS; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; DYSPHAGIA; DYSPNEA; FEMALE; HUMAN; ICD-10; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; NORWAY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HOSPITAL;

ADULT; DERMATOMYOSITIS; HUMANS; NORWAY; POLYMYOSITIS; PREVALENCE;

EID: 84940387584     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205127     Document Type: Article

References (33)

1. Lundberg I, Chinoy H, Cox AJ. Polymyositis and dermatomyositis. In: Biljsma J, ed. Eular textbook on rheumatic diseases. London: BMJ Group, 2012:568-93.
2. Dimachkie MM, Barohn RJ. Inclusion body myositis. Semin Neurol 2012;32:237-45.
3. Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011;63:3439-47.
4. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
5. Tansley S, Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis-moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 2013 [epub ahead of print].
6. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
7. O'Hanlon TP, Miller FW. Genetic risk and protective factors for the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2009;11:287-94.
8. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635-8.
9. Bohan A, Peter JB, Bowman RL, et al. Computer-Assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
10. Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-35.
11. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
12. Christopher-Stine L. Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr OpinRheumatol 2010;22:623-6.
13. Hoogendijk JEAA, Lecky BR, Choy EH, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-45.
14. Tjarnlund ABM, Bottai M, Rider LG, et al. Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, The EULAR Journal 2013;72(Supplement 3):60/OP0035.
15. Cox S, Limaye V, Hill C, et al. Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis 2010;13:117-24.
16. Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010;146:26-30.
17. Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990;17:1329-34.
18. Weitoft T. Occurrence of polymyositis in the county of Gavleborg, Sweden. Scand J Rheumatol 1997;26:104-6.
19. Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960-76. Isr J Med Sci 1980;16:197-200.
20. Kurland LT, Hauser WA, Ferguson RH, et al. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969;44:649-63.
21. Medsger TA Jr., Dawson WN Jr., Masi AT. The epidemiology of polymyositis. Am J Med 1970;48:715-23.
22. Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974;81:182-9.
23. Patrick M, Buchbinder R, Jolley D, et al. Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J Rheumatol 1999;26:1094-100.
24. Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain 1966;89:747-68.
25. Vargas-Leguas H, Selva-O'Callaghan A, Campins-Marti M, et al. [Polymyositis-dermatomyositis: incidence in Spain (1997-2004)]. Med Clin 2007;129:721-4.
26. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 2012;13:103.
27. Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012;45:676-83.
28. Bernatsky S, Joseph L, Pineau CA, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009;68:1192-6.
29. Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiationassociated protein 5-Associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 2013;65:1307-15.
30. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009;68:1621-5.
31. Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskeletal Dis 2011;3:315-24.
32. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
33. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006;8:R13.